Qingshan Li
Guangzhou, 510220, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Corrigendum to "Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations" [Translational Oncology 58 (2025) 102467].
Journal: Translational oncology
Published: May 25, 2026
Exosomal miRNA as a biomarker for diagnosis and prognosis, and a new target for regulating treatment resistance in DLBCL: a research progress narrative review.
Journal: Translational cancer research
Published: March 09, 2026
Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations.
Journal: Translational oncology
Published: July 06, 2024
High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients.
Journal: International immunopharmacology
Published: February 28, 2021
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.
Journal: Cancer cell international
Published: December 15, 2020
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Journal: Journal of cancer research and clinical oncology
Published: July 25, 2020
Role of heterogeneous regulatory T cells in the tumor microenvironment.
Journal: Pharmacological research
Published: November 10, 2019
Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 24, 2018
PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Journal: Biochemical pharmacology
Published: December 03, 2017
Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
Published: November 23, 2017
Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma.
Journal: International journal of oncology
Published: November 22, 2017
Last Updated: 09/26/2026